GEN-MKT-18-7897-A
Aug 24, 2017 | Biopharma, Blogs | 0 comments
Biopharmaceutical development is booming and now an integral part of many pharmaceutical company pipelines. While these emerging biologics present exciting opportunities for the industry, their sophistication is challenging the limits of characterization at all stages of discovery and development.
Biologic structures are larger and more complex than traditional small molecule drugs, making characterization considerably more challenging and time-consuming. To reliably develop these biologics, and to keep pace, a new level of sophistication in characterization technologies and workflows is needed.
SCIEX hardware and software solutions have been specifically developed to reduce the complexity of biologics characterization. We bring you four technologies in a single powerful, integrated solution: based on the SCIEX X500B QTOF System and BioPharmaView™ Software. With streamlined workflows, SCIEX Biologics Solutions simplify standardized intact protein analysis, subunit analysis, peptide mapping, and comparability analyses.
But don’t just take our word for it, we can prove it too. We have demonstrated the compelling capabilities of our Biologics Solutions in the characterization the biotherapeutic trastuzumab. Trastuzumab is a recombinant IgG1 monoclonal antibody for the treatment of Her2 positive breast cancer. In this case study, we analyzed and compared trastuzumab therapeutic samples from two different manufacturers to assess comparability.Download the Full Report >
To read the full comparative study of the trastuzumab samples with X500B QTOF system and BioPharmaView Software, download the report by completing the short form on the right.
With SCIEX Biologics Solutions the complexity of biotherapeutics characterization is made routine. The powerful hardware of the SCIEX X500B QTOF in combination with SCIEX OS point-and-click software ensures that high-quality data can be acquired in just a few clicks. And BioPharmaView Software simplifies and streamlines complex characterization tasks with its straightforward “click-compare-report” format.Download the Full Report >
Trifluoroacetic acid (TFA) is emerging as one of the most concerning ultrashort-chain PFAS in Europe’s food supply – particularly in cereals, a staple consumed daily by millions. A report from PAN Europe reveals a widespread and largely unmonitored contamination trend that raises serious questions about food safety, regulatory blind spots, and future monitoring strategies.
PFAS analysis is complex, but expert guidance doesn’t have to be. In this episode of our ‘Ask the PFAS expert series’, we’re joined by Michael Scherer, Application Lead for Food and Environmental, to answer the most pressing questions in PFAS analysis. From why LC-MS/MS systems are the gold standard for analyzing diverse PFAS compounds, to which EU methods deliver reliable results for drinking water, and to practical steps to prevent contamination, Michael shares actionable insights to help laboratories achieve accuracy, consistency, and confidence in their workflows.
During an LC-MS/MS experiment, traditional fragmentation techniques like collision-induced dissociation (CID) have long been the gold standard. Electron-activated dissociation (EAD) is emerging as a transformative tool that enhances structural elucidation, particularly for complex or labile metabolites.
Posted by
You must be logged in to post a comment.
Share this post with your network